Hanmi initiates Phase 1 trial of BH3120 with pembrolizumab in advanced solid tumors
Hanmi Pharmaceutical Company is conducting Phase 1 trial to evaluate BH3120 alone and with pembrolizumab in patients with advanced or metastatic solid tumors.
Company
Pharmaceutical intelligence for Hanmi Pharmaceutical Company with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.